But Eli Lilly's supply woes began to ease earlier this year, and the Food and Drug Administration removed tirzepatide, the active ingredient in Mounjaro and Zepbound, from its shortage list.

However, Novo Nordisk's chief rival in the weight loss space shouldn't be slept on. Eli Lilly (LLY -3.37%), the developer of Mounjaro, has proven that it can compete with Novo Nordisk at a high level.

Eli Lilly filed a complaint with the U.S. International Trade Commission on Thursday to block companies from importing and selling cheaper versions of its blockbuster drug Mounjaro online ...

Eli Lilly and Company releases its Q1 2023 earnings on Thursday, 27th April. LLY's revenue growth has been so-so, earnings hit-and-miss, click for our preview.

T he drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered ...